A61K 2239/38
Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by the
Official title: characterised by the dose, timing or administration schedule
A61K2239/38 (Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by the) appears on 2,183 US grants and 4,818 published applications in this corpus.
Search patents in A61K- Granted patents
- 2,183
- Published applications
- 4,818
- Assignees
- 1,512
- Inventors
- 7,214
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 5 | 0 |
| 1995 | 5 | 0 |
| 1996 | 2 | 0 |
| 1997 | 8 | 0 |
| 1998 | 20 | 0 |
| 1999 | 9 | 0 |
| 2000 | 14 | 0 |
| 2001 | 12 | 7 |
| 2002 | 16 | 52 |
| 2003 | 8 | 54 |
| 2004 | 15 | 68 |
| 2005 | 9 | 46 |
| 2006 | 19 | 68 |
| 2007 | 12 | 30 |
| 2008 | 17 | 39 |
| 2009 | 21 | 54 |
| 2010 | 47 | 85 |
| 2011 | 30 | 81 |
| 2012 | 27 | 59 |
| 2013 | 52 | 96 |
| 2014 | 48 | 108 |
| 2015 | 50 | 123 |
| 2016 | 76 | 136 |
| 2017 | 73 | 162 |
| 2018 | 99 | 243 |
| 2019 | 90 | 333 |
| 2020 | 167 | 400 |
| 2021 | 158 | 473 |
| 2022 | 178 | 537 |
| 2023 | 201 | 458 |
| 2024 | 220 | 536 |
| 2025 | 257 | 336 |
| 2026 | 207 | 234 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
- Methods for stem cell transplantation1 Oct 2026US 2026/0294975 A1The UAB Research Foundation
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells384US 6,905,681 B1Genetics Institute, Inc. · 2005
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014